Australia markets close in 5 hours 23 minutes

Catalyst Biosciences, Inc. (CBIO)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
0.5500-0.0076 (-1.36%)
At close: 03:59PM EST
0.5500 0.00 (0.00%)
After hours: 04:30PM EST
Full screen
Trade prices are not sourced from all markets
Previous close0.5576
Open0.5500
Bid0.5469 x 900
Ask0.5578 x 800
Day's range0.5461 - 0.5598
52-week range0.0920 - 0.6200
Volume77,073
Avg. volume769,904
Market cap17.32M
Beta (5Y monthly)1.70
PE ratio (TTM)1.45
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend date21 Sept 2022
1y target estN/A
  • GlobeNewswire

    Catalyst Biosciences, Inc. Announces September 21, 2022 as the Ex-Dividend Date for Special Cash Dividend of $1.43 per share

    SOUTH SAN FRANCISCO, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) (“Catalyst,” the “Company” or “we”) today announced that the ex-dividend date for the special, one-time cash dividend of $1.43 per share to holders of the Company’s Common Stock previously disclosed by the Company will be September 21, 2022. The dividend is payable on September 20, 2022 to stockholders of record at the close of business on September 6, 2022. Stockholders of record on the rec

  • GlobeNewswire

    Catalyst Biosciences, Inc. Declares Special Cash Dividend of $1.43 per share

    SOUTH SAN FRANCISCO, Calif., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) (“Catalyst,” the “Company” or “we”) today announced that the Board of Directors has declared a special, one-time cash dividend of $1.43 per share to holders of the Company’s Common Stock. The dividend is payable on September 20, 2022 to stockholders of record at the close of business on September 6, 2022. The aggregate amount of the payment to be made in connection with this special dividend

  • GlobeNewswire

    Catalyst Biosciences, Inc. Announces Dismissal of JDS1 Litigation

    Company to Announce a Record Date for Initial Distribution in Due CourseSOUTH SAN FRANCISCO, Calif., Aug. 19, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) (“Catalyst,” the “Company” or “we”) today announced that JDS1, LLC, one of the Company’s stockholders, has dismissed its lawsuits against the Company. “With the JDS1 litigation behind us, the Board of Directors will be meeting to determine the details of an initial distribution of capital, and we will communicate this inf